Export
Model List of Essential Medicines
clear
Found 290 recommendations for 88 medicines and 23 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
-
Abiraterone General information
SectionHormones and antihormones- Oral > Solid: 250 mg; 500 mg
Indications -
Adalimumab General information
SectionImmunomodulators for non-malignant disease- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
-
Afatinib General information
SectionTargeted therapiesIndicationsTherapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung -
All-trans retinoic acid General information
SectionTargeted therapies- Oral > Solid: 10 mg capsule
-
Allopurinol General information
SectionSupportive medicines- Oral > Solid: 100 mg; 300 mg
Indications -
Anastrozole General information
SectionHormones and antihormones- Oral > Solid: 1 mg tablet
-
Arsenic trioxide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
-
Asparaginase General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
Indications -
Azathioprine General information
SectionImmunomodulators for non-malignant disease- Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)
- Oral > Liquid: 10 mg per mL
- Oral > Solid > tablet: 25 mg; 50 mg (scored)
-
Bendamustine General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
-
Bicalutamide General information
SectionHormones and antihormones- Oral > Solid: 50 mg
Indications -
Bleomycin General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)
-
Bortezomib General information
SectionTargeted therapies- Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
Indications -
Calcium folinate (leucovorin calcium) General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
-
Capecitabine General information
SectionCytotoxic medicines- Oral > Solid > tablet: 150 mg; 500 mg
-
Carboplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
IndicationsOther specified gliomas of brain Other specified carcinomas of ovary Retinoblastoma Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Malignant neoplasms of kidney, except renal pelvis Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Other specified malignant neoplasms of the ovary Germ cell tumour of testis -
Certolizumab pegol General information
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis -
Chlorambucil General information
SectionCytotoxic medicines- Oral > Solid: 2 mg tablet
-
Ciclosporin General information
SectionImmunomodulators for non-malignant disease- Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
- Oral > Liquid: 100 mg per mL
- Oral > Solid > capsule: 25 mg
-
Cisplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL
IndicationsOther specified gliomas of brain Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Germ cell tumour of testis Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri -
Cyclophosphamide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid > dosage form: 25 mg; 50 mg
IndicationsOther specified malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of breast Chronic lymphocytic leukaemia or small lymphocytic lymphoma Rhabdomyosarcoma primary site Hodgkin lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Other specified gliomas of brain Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive -
Cytarabine General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial
Indications -
Dacarbazine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection
Indications -
Dactinomycin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 µg in vial powder for injection
-
Dasatinib General information
SectionTargeted therapies- Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
-
Daunorubicin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
-
Dexamethasone General information
SectionHormones and antihormones- Oral > Solid: 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
-
Docetaxel General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
-
Doxorubicin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
IndicationsMalignant neoplasms of breast Hodgkin lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Other specified malignant neoplasms of breast Anaplastic large cell lymphoma, ALK-positive Ewing sarcoma of bone and articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site -
Doxorubicin (as pegylated liposomal) General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
Indications -
Enzalutamide General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to abiraterone for Malignant neoplasms of prostate -
Erlotinib General information
SectionTargeted therapies- Oral > Solid: 100 mg; 150 mg
-
Etanercept General information
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis -
Etoposide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
- Oral > Solid: 100 mg capsule; 50 mg capsule
IndicationsBurkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Hodgkin lymphoma Retinoblastoma Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative -
Everolimus General information
SectionTargeted therapies- Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
- Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg
Indications -
Filgrastim General information
SectionImmunomodulators- Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
Indications -
Fludarabine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
- Oral > Solid: 10 mg tablet (fludarabine phosphate)
-
Fluorouracil General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per mL in vial
-
Flutamide General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to bicalutamide for Malignant neoplasms of prostate -
Gefitinib General information
SectionTargeted therapiesIndicationsTherapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung -
Gemcitabine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
-
Golimumab General information
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis -
Goserelin General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate -
Hydrocortisone General information
SectionHormones and antihormones- Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
-
Hydroxycarbamide (hydroxyurea) General information
SectionCytotoxic medicines- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
-
Ibrutinib General information
SectionTargeted therapies- Oral > Solid: 140 mg
-
Ifosfamide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
IndicationsOther specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive -
Imatinib General information
SectionTargeted therapies- Oral > Solid: 100 mg; 400 mg
-
Infliximab General information
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis -
Irinotecan General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
-
Lenalidomide General information
SectionImmunomodulators- Oral > Solid: 25 mg
Indications -
Leuprorelin General information
SectionHormones and antihormones- Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
-
Melphalan General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection
- Oral > Solid: 2 mg
Indications -
Mercaptopurine General information
SectionCytotoxic medicines- Oral > Liquid: 20 mg per mL
- Oral > Solid: 50 mg tablet
-
Mesna General information
SectionSupportive medicines- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg
IndicationsOsteosarcoma of bone and articular cartilage of other specified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis -
Methotrexate General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
- Oral > Solid: 2.5 mg (as sodium salt)
IndicationsLymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Malignant trophoblastic neoplasms of placenta Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis -
Methylprednisolone General information
SectionHormones and antihormones- Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
-
Nilotinib General information
SectionTargeted therapies- Oral > Solid > capsule: 150 mg; 200 mg
-
Nilutamide General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to bicalutamide for Malignant neoplasms of prostate -
Nivolumab General information
SectionImmunomodulators- Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
Indications -
Oxaliplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
-
Paclitaxel General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 6 mg per mL
IndicationsOther specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Kaposi sarcoma of unspecified primary site Other specified malignant neoplasms of breast Other specified carcinomas of ovary Malignant neoplasms of breast Malignant neoplasms of cervix uteri -
Pegaspargase General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
Indications -
Pegfilgrastim General information
SectionImmunomodulators- Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
Indications -
Pembrolizumab General information
SectionImmunomodulatorsIndicationsTherapeutic equivalent to nivolumab for Melanoma of skin -
Prednisolone General information
SectionHormones and antihormones- Oral > Solid: 5 mg; 25 mg
- Oral > Liquid: 5 mg per mL
IndicationsPlasma cell myeloma Follicular lymphoma Lymphoid leukaemia, not elsewhere classified Malignant neoplasms of prostate Chronic lymphocytic leukaemia or small lymphocytic lymphoma Hodgkin lymphoma Diffuse large B-cell lymphomas Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis -
Prednisone General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to prednisolone for Plasma cell myeloma Therapeutic equivalent to prednisolone for Follicular lymphoma Therapeutic equivalent to prednisolone for Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone for Malignant neoplasms of prostate Therapeutic equivalent to prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone for Hodgkin lymphoma Therapeutic equivalent to prednisolone for Diffuse large B-cell lymphomas Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone for Langerhans cell histiocytosis -
Procarbazine General information
SectionCytotoxic medicines- Oral > Solid > capsule: 50 mg (as hydrochloride)
Indications -
Rasburicase General information
SectionSupportive medicines- Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution
Indications -
Realgar-indigo naturalis formulation General information
SectionCytotoxic medicines- Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
-
Rituximab General information
SectionTargeted therapies- Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
-
Tacrolimus General information
SectionImmunomodulators for non-malignant disease- Parenteral > General injections > IV: 5 mg per mL in 1 mL vial
- Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension
- Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)
-
Tamoxifen General information
SectionHormones and antihormones- Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
-
Thalidomide General information
SectionImmunomodulators- Oral > Solid: 50 mg
Indications -
Tioguanine General information
SectionCytotoxic medicines- Oral > Solid: 40 mg
Indications -
Trastuzumab General information
SectionTargeted therapies- Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
Indications -
Triptorelin General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate -
Vinblastine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)
Indications -
Vincristine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
IndicationsOther specified gliomas of brain Malignant trophoblastic neoplasms of placenta Follicular lymphoma Kaposi sarcoma of unspecified primary site Rhabdomyosarcoma primary site Hodgkin lymphoma Diffuse large B-cell lymphomas Retinoblastoma Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Langerhans cell histiocytosis -
Vinorelbine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
- Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
- Oral > Solid > capsule: 20 mg; 30 mg; 80 mg
-
Zoledronic acid General information
SectionSupportive medicines- Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle